$CYDY {{Press release @ Upticknewswire.com}} CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval “We are elated at the distinction of partnering with the world’s preeminent biologics manufacturer for our franchise-defining drug,” stated Nader Pourhassan, Ph.D, CytoDyn’s President, CEO and director.  “In the last four years, Samsung BioLogics has been among the most successful, consistent and highest quality biologics manufacturers in the world
CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval